Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2024Open Access

Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results

View Full Paper
Ask AI
Bookmark
Share

Authors

GHGirish HarinathVLVirginia LeeANAndy Nyquist

Discussion

Loading...

Member takes

Overview

Randomized double-blind trial demonstrates weekly rapamycin improves lean tissue mass in healthy older adults, suggesting targeted healthspan benefits.

Key Points

  • Weekly rapamycin improved lean tissue mass and self-reported pain in women, whereas visceral adiposity remained unchanged across all participants.
  • Lean tissue mass increased significantly with effect size ε 2 =0.202 at 10mg rapamycin, while blood biomarkers remained within normal clinical ranges.
  • Double-blinded, randomized, placebo-controlled trial monitored dxa scan metrics over 48 weeks, supporting broader evaluations of rapamycin dosing.

Cite This Study

Harinath et al. (2024) studied this question.

synapsesocial.com/papers/68e5b4dfb6db64358754d7b6https://doi.org/10.1101/2024.08.21.24312372
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1mTOR inhibition improves immune function in the elderly2014 · 805 citations
  2. 2Subjective well-being in non-obese individuals depends strongly on body composition2021 · 19 citations
  3. 3Effect of rapamycin on aging and age-related diseases—past and future2020 · 310 citations
  4. 4mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases2018 · 81 citations
  5. 5Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization2022 · 129 citations